TROPOnin FRAGMentation in Myocardial Injury Study
Launched by UNIVERSITY OF TURKU · Jul 7, 2020
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The TROPOnin FRAGMentation in Myocardial Injury Study is looking into how a protein called Troponin T (TnT) behaves in patients with heart injuries, specifically those experiencing a type of heart attack known as Acute Myocardial Infarction. Researchers have found that TnT can break into smaller pieces, or fragments, but they don’t fully understand what this means for patients. This study aims to find out how often TnT fragmentation occurs in different groups of patients, especially those with other health issues that might affect TnT levels.
To participate in this study, you need to be between the ages of 65 and 74 and have a sample of TnT collected. Unfortunately, if you are under 18, you won't be eligible. If you join the study, you can expect to help researchers gather important information that could improve how doctors diagnose and treat heart conditions in the future. This research could lead to a better understanding of TnT and how it may help identify heart issues more accurately in patients with other health problems.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Troponin T fragmentation sample collected from a recruited patient.
- Exclusion Criteria:
- • Age \<18
About University Of Turku
The University of Turku, established in 1920, is a leading research institution located in Finland, renowned for its commitment to advancing knowledge and innovation across various fields. As a clinical trial sponsor, the university leverages its extensive expertise and collaborative networks to conduct rigorous and ethically sound research, aiming to improve healthcare outcomes and contribute to scientific advancements. With a focus on interdisciplinary approaches, the University of Turku fosters an environment that encourages groundbreaking studies, ultimately enhancing the quality of life through evidence-based medical solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, Varsinais Suomi, Finland
Zürich, , Switzerland
Patients applied
Trial Officials
Juhani K Airaksinen, MD, PhD
Principal Investigator
University of Turku
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials